Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
This phase I study will characterize the safety, tolerability, and maximum tolerated dose and dose-limiting toxicity of weekly bolus Topotecan when administered in combination with to different dosing regimens of docetaxel. We will also evaluate any anti-tumor activity of the combination regimen.
Epistemonikos ID: 4ef343eb4da9688377591e78666baa94994472db
First added on: May 04, 2024